Prot# KAG-302: Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Comparing Three Doses of Tanespimycin in Patients with Relapsed-Refractory Multiple Myeloma

Project: Research project

Project Details

StatusFinished
Effective start/end date11/1/07 → 5/1/13

Funding

  • PharmaNet, Inc. (KAG-302 // KAG-302)
  • Kosan Biosciences Incorporated (KAG-302 // KAG-302)